Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berinert for DGF prevention in high-risk kidney transplant
NCT04696146Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of c1-esterase inhibitor in delayed graft function (DGF), ischemia-reperfusion injury (IRI), sponsored by Cedars-Sinai Medical Center. Started Mar 2021; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
delayed graft function (DGF)ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT04696146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696146.